|
1) Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008; 117: 207-31
|
|
|
|
2) Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369: 71-7
|
|
|
|
|
|
3) Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335: 1194-9
|
|
|
|
|
|
4) Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in ab-dominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007; 30: 27-32
|
|
|
|
|
|
5) von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon？ Eur Heart J. 2007; 28: 2830-1
|
|
|
|
|
|
6) Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: 561-4
|
|
|
|
|
|
7) Van Gaal LF, Rissanen AM, Scheen AJ, et al; RIO-Europe Study Group. Effects of the can-nabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in over-weight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-97
|
|
|
|
|
|
8) Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353: 2111- 20
|
|
|
|
|
|
9) Scheen AJ, Finer N, Hollander P, et al; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006; 368: 1660-72
|
|
|
|
|
|
10) Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295: 761-75
|
|
|
|
|
|
11) Wadman M. Rimonabant adds appetizing choice to slim obesity market. Nat Med. 2006; 12: 27
|
|
|
|
|
|
12) Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006; 114: 974-84
|
|
|
|
|
|
13) Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003; 63: 908-14
|
|
|
|
|
|
14) Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol. 2006; 69: 471-8
|
|
|
|
|
|
15) Bessesen DH. Update on obesity. J Clin Endocrinol Metab. 2008; 93: 2027-34
|
|
|
|
|
|
16) Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006; 5: 919-31
|
|
|
|
|
|
17) Nissen SE, Nicholls SJ, Wolski K, et al; STRADIVARIUS Investigators. Effect of rimo-nabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008; 299: 1547-60
|
|
|
|
|
|
18) Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006; 4: 275-82
|
|
|
|
|
|
19) Rosenstock J, Hollander P, Gadde KM, et al. OBD-202 Study Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007; 30: 1480-6
|
|
|
|
|
|
20) Febbraio MA. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest. 2007; 117: 841-9
|
|
|
|
|
|
21) Yoshimoto R, Miyamoto Y, Shimamura K, et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A. 2006; 103: 13866-71
|
|
|
|
|
|
22) Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443: 709-12
|
|
|
|
|
|
23) Franco C, Andersson B, Lonn L, et al. Growth hormone reduces inflammation in postmeno-pausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007; 92: 2644-7
|
|
|
|
|
|
24) Pasarica M, Zachwieja JJ, Dejonge L, et al. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab. 2007; 92: 4265-70
|
|
|
|
|
|
25) Batterham RL, ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007; 450: 106-9
|
|
|
|
|
|
26) Vrang N, Madsen AN, Tang-Christensen M, et al. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R367-75
|
|
|
|
|
|
27) Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007; 92: 1754-7
|
|
|
|
|
|
28) Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007; 293: E620-7
|
|
|
|
|
|
29) Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007; 92: 2977-83
|
|
|
|
|
|
30) Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008; 105: 7257-62
|
|
|
|
|
|
31) Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439: 484-9
|
|
|
|
|
|
32) Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes. 2007; 56: 239-47
|
|
|
|
|
|
33) Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29
|
|
|
|
|
|
34) Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab. 2008; 294: E778-84
|
|
|
|
|
|
35) Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adipo-nectin/ACRP30. Nat Med. 2002; 8: 731
|
|
|
|
|
|
36) Ohashi K, Ouchi N, Kihara S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004; 43: 1195-200
|
|
|
|
|
|
37) Guo C, Ricchiuti V, Lian BQ, et al. Mineralo-corticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008; 117: 2253-61
|
|
|
|
|
|
38) Farooqi S. Treating obesity: does antagonism of NPY fit the bill？ Cell Metab. 2006; 4: 260-2
|
|
|
|
|